Conjugate Meningococcal Vaccines Development: GSK Biologicals Experience

Table 5

rSBA-MenA, rSBA-MenC, rSBA-MenW-135, and rSBA-MenY antibody response one month [87, 91] or 42 days [90] after one dose of MenACWY-TT in toddlers (ATP immunogenicity cohort).

Reference	Age group	Vaccine	𝑁	%≥1 : 8 [95% CI]	%≥1 : 128 [95% CI]	GMT [95% CI]
rSBA-MenA
Knuf et al., 2010 [87]	12–14 months	MenACWY-TT	42	100 [91.6–100]	100 [91.6–100]	5665.2 [4086.0–7854.9]
Vesikari et al., 2011 [90]	12–23 months	MenACWY-TT	354	99.7 [98.4–100]	99.7 [98.4–100]	2205.0 [2007.8–2421.6]
		MenACWY-TT + MMRV	360	100 [99.0–100]	99.7 [98.5–100]	2085.9 [1905.3–2283.6]
Knuf et al., 2011 [91]	12–23 months	MenACWY-TT	183	98.4 [95.3–99.7]	97.8 [94.5–99.4]	3169.9 [2577.2–3898.8]
		MenACWY-TT*	178	100 [97.9–100]	100 [97.9–100]	1938.3 [1699.1–2211.2]
		MenACWY-TT + DTPa-HBV-IPV/Hib	193	100 [98.1–100]	100 [98.1–100]	3152.9 [2752.5–3611.4]
rSBA-MenC
Knuf et al., 2010 [87]	12–14 months	MenACWY-TT	42	100 [91.6–100]	95.2 [83.8–99.4]	983.5 [718.7–1345.9]
		MenC-CRM197	46	97.8 [88.5–100]	87.0 [73.7–95.1]	372.5 [257.7–538.4]
Vesikari et al., 2011 [90]	12–23 months	MenACWY-TT	354	99.7 [98.4–100]	95.8 [93.1–97.6]	477.6 [437.3–521.6]
		MenACWY-TT + MMRV	357	100 [99.0–100]	94.4 [91.5–96.5]	519.0 [470.9–571.9]
		MenC-CRM197	121	97.5 [92.9–99.5]	70.2 [61.3–78.2]	212.3 [170.0–265.2]
Knuf et al., 2011 [91]	12–23 months	MenACWY-TT	183	97.3 [93.7–99.1]	94.0 [89.5–97.0]	828.7 [672.4–1021.4]
		MenACWY-TT*	178	100 [97.9–100]	88.2 [82.5–92.5]	386.0 [333.9–446.2]
		MenACWY-TT + DTPa-HBV-IPV/Hib	191	100 [98.1–100]	99.0 [96.3–99.9]	879.7 [763.1–1014.0]
		MenC-CRM197	114	98.2 [93.8–99.8]	89.5 [82.3–94.4]	691.4 [520.8–917.9]
rSBA-MenW-135
Knuf et al., 2010 [87]	12–14 months	MenACWY-TT	43	100 [91.8–100]	100 [91.8–100]	3975.2 [3065.7–5154.5]
Vesikari et al., 2011 [90]	12–23 months	MenACWY-TT	354	100 [99.0–100]	99.4 [98.0–99.9]	2681.7 [2453.1–2931.6]
		MenACWY-TT + MMRV	360	100 [99.0–100]	100 [99.0–100]	2055.8 [1871.0–2258.9]
Knuf et al., 2011 [91]	12–23 months	MenACWY-TT	186	98.4 [95.4–99.7]	96.8 [93.1–98.8]	4022.3 [3269.2–4948.8]
		MenACWY-TT*	179	100 [98.0–100]	99.4 [96.9–100]	2466.4 [2175.4–2796.4]
		MenACWY-TT + DTPa-HBV-IPV/Hib	193	100 [98.1–100]	100 [98.1–100]	4147.0 [3670.1–4685.8]
rSBA-MenY
Knuf et al., 2010 [87]	12–14 months	MenACWY-TT	42	100 [91.6–100]	100 [91.6–100]	2295.1 [1701.5–3095.8]
Vesikari et al., 2011 [90]	12–23 months	MenACWY-TT	354	100 [99.0–100]	99.7 [98.4–100]	2729.4 [2472.7–3012.8]
		MenACWY-TT + MMRV	359	100 [99.0–100]	99.7 [98.5–100]	2282.4 [2051.3–2539.5]
Knuf et al., 2011 [91]	12–23 months	MenACWY-TT	185	97.3 [93.8–99.1]	96.2 [92.4–98.5]	3167.7 [2521.9–3978.9]
		MenACWY-TT*	179	99.4 [96.9–100]	99.4 [96.9–100]	2446.9 [2088.5–2866.8]
		MenACWY-TT + DTPa-HBV-IPV/Hib	192	100 [98.1–100]	100 [98.1–100]	3461.8 [2990.1–4007.9]

𝑁: numbers of subjects with available data, %: percentage of subjects with titre within the specified range, 95% CI: 95% confidence interval, GMT: Geometric Mean Titre, *MenACWY-TT given one month after DTPa-HBV-IPV/Hib vaccine, Results of this table were previously published [87, 90, 91].